SCHEMBL3006435

SCHEMBL3006435

COc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cc(Br)ccc4OC)CC3)n2)c(OC)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
GAA P10253 2/20 0.37
LMNA P02545 2/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
ALOX15 P16050 1/20 0.36
F2RL3 Q96RI0 7/20 0.36
DRD2 P14416 2/20 0.35
DRD4 P21917 2/20 0.35
DRD3 P35462 2/20 0.35
PPARG P37231 1/20 0.35
GFER P55789 1/20 0.35
NCOA2 Q15596 1/20 0.35
NCOA1 Q15788 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008649 0.94 ALDH1A1 (0.38) MAPTALDH1A1HPGDHSD17B10L3MBTL1
SCHEMBL3010895 0.94 MAPT (0.42) MAPTALDH1A1HPGDHSD17B10L3MBTL1
SCHEMBL15671698 0.91 MAPT (0.36) MAPTALDH1A1HPGDHSD17B10LMNA
SCHEMBL3011425 0.91 MAPT (0.39) MAPTALDH1A1HPGDHSD17B10L3MBTL1
SCHEMBL3010966 0.90 MAPT (0.38) MAPTALDH1A1HSD17B10LMNARAB9A
SCHEMBL3015530 0.90 DRD2 (0.40) MAPTALDH1A1HPGDGAALMNA
SCHEMBL3014666 0.90 ALDH1A1 (0.41) MAPTALDH1A1HPGDHSD17B10L3MBTL1
SCHEMBL3013075 0.90 MAPT (0.40) MAPTALDH1A1HPGDHSD17B10L3MBTL1
SCHEMBL3007519 0.88 MAPT (0.37) MAPTALDH1A1HSD17B10L3MBTL1LMNA
SCHEMBL3015773 0.88 GAA (0.38) MAPTALDH1A1HPGDHSD17B10L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885ALDH1A1 3510/4885HPGD 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.